<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Condylomata acuminata (anogenital warts): Management of external condylomata acuminata in adult males</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Condylomata acuminata (anogenital warts): Management of external condylomata acuminata in adult males</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Condylomata acuminata (anogenital warts): Management of external condylomata acuminata in adult males</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ted Rosen, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Callen, MD, FACP, FAAD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 09, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3942547159"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Condylomata acuminata (CA), also known as anogenital warts, are manifestations of anogenital human papillomavirus (HPV) infection. CA manifest as variably sized and shaped soft papules or plaques on anogenital skin  (<a class="graphic graphic_picture graphicRef108140 graphicRef60946 graphicRef51759 graphicRef108145 graphicRef108144 graphicRef108141 graphicRef108146 graphicRef108147" href="/z/d/graphic/108140.html" rel="external">picture 1A-H</a>).</p><p>A diagnosis of CA can have negative psychosocial effects and may be accompanied by symptoms, such as pruritus, pain, and bleeding. Some cases of CA spontaneously resolve; however, spontaneous resolution is unpredictable. Most patients desire treatment.</p><p>Effective treatment options for CA include patient-applied and clinician-administered therapies. First-line patient-applied therapies include <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a>, <a class="drug drug_general" data-topicid="10218" href="/z/d/drug information/10218.html" rel="external">podophyllotoxin</a>, and <a class="drug drug_general" data-topicid="9452" href="/z/d/drug information/9452.html" rel="external">sinecatechins</a>. First-line clinician-administered treatments are cryotherapy, <a class="drug drug_general" data-topicid="10296" href="/z/d/drug information/10296.html" rel="external">trichloroacetic acid</a> (TCA) and bichloroacetic acid (BCA), surgical excision, electrosurgery, and laser therapy. The selection of therapy should be individualized and based upon consideration of the extent of disease, patient preference, cost, adverse effects, treatment availability, and the response to previous treatments.</p><p>The management of external CA in adolescent and adult males will be reviewed here. The diagnosis of CA, the management of vulvar or vaginal CA, and CA in children are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/99981.html" rel="external">"Condylomata acuminata (anogenital warts) in adults: Epidemiology, pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5458.html" rel="external">"Condylomata acuminata (anogenital warts): Treatment of vulvar and vaginal warts"</a> and  <a class="medical medical_review" href="/z/d/html/13732.html" rel="external">"Condylomata acuminata (anogenital warts) in children"</a>.)</p><p class="headingAnchor" id="H3180835498"><span class="h1">PATIENT COUNSELING</span><span class="headingEndMark"> — </span>A diagnosis of CA is often distressing and associated with concerns regarding cosmetic appearance, stigmatization, personal health, and sexual relationships. Educating patients about human papillomavirus (HPV) infection and CA is an important component of management. Patients may benefit from the following information:</p><p class="bulletIndent1"><span class="glyph">●</span>HPV is a common viral infection that manifests in some patients as anogenital warts. HPV infection is acquired through direct genital contact. Most people acquire HPV infection at some point during their lifetime. (See  <a class="medical medical_review" href="/z/d/html/99981.html" rel="external">"Condylomata acuminata (anogenital warts) in adults: Epidemiology, pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infection may be acquired weeks to many months prior to the appearance of anogenital warts. The timing of infection cannot be confirmed. Therefore, the appearance of anogenital warts does not guarantee infidelity within a current sexual relationship. (See  <a class="medical medical_review" href="/z/d/html/99981.html" rel="external">"Condylomata acuminata (anogenital warts) in adults: Epidemiology, pathogenesis, clinical features, and diagnosis", section on 'Transmission'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with anogenital warts may be at risk for other sexually transmitted diseases. (See  <a class="medical medical_review" href="/z/d/html/99981.html" rel="external">"Condylomata acuminata (anogenital warts) in adults: Epidemiology, pathogenesis, clinical features, and diagnosis", section on 'Other sexually transmitted diseases'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Individuals with anogenital warts can transmit HPV to sexual partners. Patients should inform current sexual partners of their diagnosis. Sexual partners may benefit from an evaluation for anogenital warts and other sexually transmitted diseases [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are a variety of effective treatments for anogenital warts. Without treatment, anogenital warts may spontaneously resolve, persist, or progress. It is estimated that approximately one-third of anogenital warts regress without treatment within four months [<a href="#rid2">2,3</a>]. It is not possible to predict which anogenital warts will resolve without treatment [<a href="#rid4">4,5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HPV infection can remain after successful removal of anogenital warts and may be transmitted to other individuals even if warts are no longer visible. It is unclear whether eradicating anogenital warts decreases future transmission of HPV. Condom use may help to reduce acquisition of anogenital warts [<a href="#rid6">6</a>]; however, HPV infection may still be transmitted through contact with infected skin that is not covered by a condom.</p><p></p><p>The negative impact of anogenital warts on psychosocial well-being has been demonstrated in multiple studies [<a href="#rid7">7-9</a>]. Clinicians should offer resources for psychologic support when needed.</p><p>Disclosure of sexually transmitted infections to sexual partners may have beneficial psychologic effects. In a survey study of 117 individuals with genital herpes, 82 individuals with HPV, and 75 individuals without sexually transmitted infection, persons who disclosed that they had a sexually transmitted infection had significantly more positive feelings about aspects of their sexual self-concept than those who had not disclosed their sexually transmitted infection [<a href="#rid10">10</a>].</p><p>Additional resources for patient information are provided. (See <a class="local">'Information for patients'</a> below.)</p><p class="headingAnchor" id="H4175735042"><span class="h1">EVALUATION FOR INTERNAL INVOLVEMENT</span><span class="headingEndMark"> — </span>Patients with external CA may have associated involvement of the urethra or anal canal. Indications for evaluating these sites are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/99981.html" rel="external">"Condylomata acuminata (anogenital warts) in adults: Epidemiology, pathogenesis, clinical features, and diagnosis", section on 'Internal involvement'</a>.)</p><p class="headingAnchor" id="H2988879892"><span class="h1">INDICATIONS FOR TREATMENT</span><span class="headingEndMark"> — </span>All patients should be offered treatment. While anogenital warts may spontaneously resolve, they also may spread or enlarge, making treatment more difficult. Therefore, deferring treatment is not recommended. Given the uncertainty regarding resolution and the negative psychosocial and physical effects of anogenital warts (eg, pruritus, pain, bleeding, interference with micturition, defecation, and sexual function), most patients desire treatment. (See  <a class="medical medical_review" href="/z/d/html/99981.html" rel="external">"Condylomata acuminata (anogenital warts) in adults: Epidemiology, pathogenesis, clinical features, and diagnosis", section on 'Clinical course'</a>.)</p><p class="headingAnchor" id="H2391134520"><span class="h1">TREATMENT OPTIONS</span><span class="headingEndMark"> — </span>Treatment options for external CA include patient-applied topical medications and clinician-administered treatments [<a href="#rid1">1</a>].</p><p>First-line patient-applied therapies include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">Imiquimod</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10218" href="/z/d/drug information/10218.html" rel="external">Podophyllotoxin</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9452" href="/z/d/drug information/9452.html" rel="external">Sinecatechins</a></p><p></p><p>First-line clinician-administered therapies include:</p><p class="bulletIndent1"><span class="glyph">●</span>Cryotherapy</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10296" href="/z/d/drug information/10296.html" rel="external">Trichloroacetic acid</a> (TCA) and bichloroacetic acid (BCA)</p><p class="bulletIndent1"><span class="glyph">●</span>Surgical removal (excision, electrosurgery, or laser)</p><p></p><p>The mechanisms of action of these interventions include antiproliferative properties (<a class="drug drug_general" data-topicid="10218" href="/z/d/drug information/10218.html" rel="external">podophyllotoxin</a>), immunomodulatory effects (<a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a> and <a class="drug drug_general" data-topicid="9452" href="/z/d/drug information/9452.html" rel="external">sinecatechins</a>), and ablative/destructive effects (cryotherapy, TCA, surgical excision, electrosurgery, and laser).</p><p>Other therapies are less commonly used for CA or reserved for refractory disease because of limited evidence for efficacy or safety concerns. (See <a class="local">'Other therapies'</a> below and <a class="local">'Refractory disease'</a> below.)</p><p class="headingAnchor" id="H4076912291"><span class="h1">TREATMENT SELECTION</span></p><p class="headingAnchor" id="H2717388554"><span class="h2">General approach</span><span class="headingEndMark"> — </span>The selection of a first-line treatment for external CA should be individualized and directed by factors such as the number, size, and location of warts; patient preference; cost considerations; adverse effects; clinician skill; and treatment availability. No single therapy has emerged as the standard of care (see <a class="local">'First-line patient-applied therapies'</a> below and <a class="local">'First-line clinician-applied therapies'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Size of anogenital warts</strong> – Although patients with single or multiple small (eg, &lt;1 cm) anogenital warts may be effectively treated with any of the patient-administered or clinician-administered first-line treatments, clinician-administered destructive therapies are often favored given the rapid results compared with long-term topical therapy. Cryotherapy is a typical first-line treatment given that it is a widely available, well-tolerated therapy that is easy to administer and does not require anesthesia. Electrosurgery is an additional favored option for the treatment of small genital warts; however, electrosurgery may result in more scarring than cryotherapy. Both cryotherapy and electrosurgery may result in local skin dyschromia; the risk is greatest in patients with moderately to darkly pigmented skin.</p><p></p><p class="bulletIndent1">Extensive disease (eg, large exophytic plaques or nodules  (<a class="graphic graphic_picture graphicRef111006" href="/z/d/graphic/111006.html" rel="external">picture 2</a>)) may be best managed with surgical excision, laser ablation, or electrosurgery. Topical agents are commonly used as adjunctive therapy for remaining disease [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient preference </strong>– Patients may express a preference for patient-applied versus clinician-applied treatments. Some patients prefer to treat CA privately at home, whereas others prefer to avoid the prolonged treatment courses associated with patient-applied therapies and prefer the rapid results of clinician-administered ablative treatments.</p><p></p><p class="bulletIndent1">Of note, patients with visual, cognitive, or physical impairments that limit their ability to identify, treat, and reach all warts are not good candidates for patient-applied treatments.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cost </strong>– The cost of topical therapies is prohibitive for some patients. Of the first-line patient-applied therapies, <a class="drug drug_general" data-topicid="10218" href="/z/d/drug information/10218.html" rel="external">podophyllotoxin</a> is the least expensive. United States pricing information is available in the drug information content available with UpToDate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects </strong>– Potential adverse effects of treatments should be reviewed with patients. Local inflammatory reactions are common side effects of <a class="drug drug_general" data-topicid="10218" href="/z/d/drug information/10218.html" rel="external">podophyllotoxin</a>, <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a>, and <a class="drug drug_general" data-topicid="9452" href="/z/d/drug information/9452.html" rel="external">sinecatechins</a>. Systemic side effects can occur from treatment with imiquimod, <a class="drug drug_general" data-topicid="9786" href="/z/d/drug information/9786.html" rel="external">podophyllin resin</a>, or intralesional interferon injections. Clinician-administered ablative therapies can result in scarring and dyspigmentation.</p><p></p><p class="bulletIndent1">Treatment-specific side effects are discussed in greater detail in the sections on specific therapies. (See <a class="local">'First-line patient-applied therapies'</a> below and <a class="local">'First-line clinician-applied therapies'</a> below and <a class="local">'Other therapies'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinician skill and treatment availability </strong>– Procedures such as cryotherapy, surgical excision, electrosurgery, and laser therapy require clinicians trained to perform the procedure and appropriate equipment.</p><p></p><p class="headingAnchor" id="H3402239983"><span class="h2">Combination therapy</span><span class="headingEndMark"> — </span>Combinations of patient-applied and clinician-administered therapies are often used in clinical practice (eg, use of a patient-applied topical therapy in-between sessions of clinician-administered treatment) in an attempt to augment the response to treatment [<a href="#rid11">11-15</a>]. However, data on the efficacy and safety of this approach are limited. A randomized trial that compared cryotherapy alone with cryotherapy followed by treatment with <a class="drug drug_general" data-topicid="9452" href="/z/d/drug information/9452.html" rel="external">sinecatechins</a> ointment in 42 patients with anogenital warts found a greater reduction in the number of anogenital warts with combination therapy [<a href="#rid13">13</a>]. In contrast, a randomized trial that compared cryotherapy plus <a class="drug drug_general" data-topicid="10218" href="/z/d/drug information/10218.html" rel="external">podophyllotoxin</a> with cryotherapy alone in 140 patients with anogenital warts did not find a statistically significant difference in rates of clearance [<a href="#rid14">14</a>]. (See <a class="local">'Second-line therapy'</a> below.)</p><p class="headingAnchor" id="H1772896778"><span class="h2">Immunosuppressed patients</span><span class="headingEndMark"> — </span>The approach to treatment in immunocompromised patients does not differ from the approach for immunocompetent patients [<a href="#rid1">1</a>]. However, wart treatment is less successful in immunocompromised patients. Longer treatment courses and closer follow-up may be necessary.</p><p class="headingAnchor" id="H4085548123"><span class="h1">FIRST-LINE PATIENT-APPLIED THERAPIES</span><span class="headingEndMark"> — </span>First-line patient-applied therapies include <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a>, <a class="drug drug_general" data-topicid="10218" href="/z/d/drug information/10218.html" rel="external">podophyllotoxin</a>, and <a class="drug drug_general" data-topicid="9452" href="/z/d/drug information/9452.html" rel="external">sinecatechins</a> [<a href="#rid1">1,16</a>].</p><p class="headingAnchor" id="H3055881450"><span class="h2">Imiquimod</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">Imiquimod</a> is an immunomodulatory drug that increases the immune response to warts [<a href="#rid17">17</a>]. Imiquimod is a powerful cytokine inducer that stimulates production of interferon-alpha, tumor necrosis factor, and interleukin (IL) 1, IL-6, and IL-8. Imiquimod 5% cream and 3.75% cream are used for the treatment of anogenital warts:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy </strong>– A systematic review of randomized trials found <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a> superior to placebo for achieving complete and partial regression of anogenital warts (relative risks 4.03, 95% CI 2.03-7.99 and 2.56, 95% CI 2.05-3.20, respectively) but did not identify superiority for recurrence rates or new wart development [<a href="#rid18">18</a>]. The quality of evidence for outcomes assessed in the review was low to very low due to risk of bias, imprecision, and inconsistency. Clearance rates from randomized trials for imiquimod 5% cream range from 35 to 75 percent [<a href="#rid19">19,20</a>]. Recurrence rates range from 6 to 26 percent [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1">Efficacy of the 3.75% concentration of <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a> also has been demonstrated in randomized trials [<a href="#rid21">21-23</a>]. In two identical, phase 3, placebo-controlled, randomized trials, 447 adolescent and adult males with anogenital warts were randomly assigned in a 2:2:1 ratio to self-treatment with imiquimod 3.75% cream, imiquimod 2.5% cream, or placebo once daily until complete clearance or a maximum of eight weeks [<a href="#rid22">22</a>]. Patients who did not achieve complete clearance by eight weeks were followed for clearance for up to an additional eight weeks (end of study). At end of study, the complete clearance rates with imiquimod 3.75% (20 and 17 percent) were superior to placebo in both trials. The complete clearance rates for imiquimod 2.5% cream (13 and 15 percent) were superior to placebo only in the second trial.</p><p></p><p class="bulletIndent1">Although reported cure rates for <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a> 5% cream appear higher than those for imiquimod 3.75% cream, the efficacy of these agents has not been directly compared and methodologic differences between studies may contribute to the disparity. An advantage of the 3.75% formulation is the shorter treatment duration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration </strong>– Patients should apply <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a> 5% cream to anogenital warts three times per week (eg, Monday, Wednesday, Friday) until there is total clearance of the anogenital warts or for a maximum of 16 weeks. A thin layer of imiquimod 5% cream should be applied to each wart and rubbed in until the cream is no longer visible. Imiquimod 5% cream should be applied prior to normal sleeping hours and left on the skin for 6 to 10 hours, after which the cream should be removed by washing the area with mild soap and water. The prescriber should demonstrate the proper application technique (including clear directions for the locations to treat and amount of medication to apply) to maximize benefit [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1">A different regimen is used for <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a> 3.75% cream. Patients should apply a thin layer of imiquimod 3.75% cream to anogenital warts once daily for eight weeks. The cream should be applied prior to normal sleeping hours and washed off after eight hours with mild soap and water [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Local inflammatory reactions, including redness, irritation, induration, ulceration, erosions, and vesicles, are common with the use of <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a> 5% cream. A rest period of several days may be taken, if necessary, because of patient discomfort or severity of the reaction. Treatment may resume once the reaction subsides. Nonocclusive dressings (eg, cotton gauze or cotton underwear) may be used in the management of skin reactions.</p><p></p><p class="bulletIndent1">In addition, hypopigmentation may develop at the site of treatment. Flu-like symptoms occur infrequently. Rare cases of vitiligo [<a href="#rid25">25-27</a>] and reversible penile curvature secondary to edema [<a href="#rid28">28</a>] have been reported in association with <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a> treatment.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">Imiquimod</a> can weaken condoms and vaginal diaphragms [<a href="#rid29">29</a>]. Sexual contact should be avoided while imiquimod is on the skin [<a href="#rid21">21</a>].</p><p></p><p class="headingAnchor" id="H1669673157"><span class="h2">Podophyllotoxin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10218" href="/z/d/drug information/10218.html" rel="external">Podophyllotoxin</a> is an antimitotic drug that can be chemically synthesized or purified from the plant families Coniferae and Berberidaceae (eg, species of <em>Juniperus</em> and <a class="drug drug_general" data-topicid="9786" href="/z/d/drug information/9786.html" rel="external">Podophyllum</a>). In the United States, podophyllotoxin is available as a 0.5% solution or gel. In other locales, podophyllotoxin may also be available as a 0.15% cream:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy </strong>– Placebo-controlled randomized trials support the efficacy of <a class="drug drug_general" data-topicid="10218" href="/z/d/drug information/10218.html" rel="external">podophyllotoxin</a> for CA [<a href="#rid30">30-33</a>]. A systematic review of randomized controlled trials found clearance rates from 45 to 83 percent with use of podophyllotoxin 0.5% solution for three to six weeks and 43 to 70 percent with use of podophyllotoxin 0.15% cream for four weeks [<a href="#rid19">19</a>]. Recurrence rates range between 13 and 100 percent [<a href="#rid19">19</a>]; differences in the criteria used to assess relapse and follow-up intervals may contribute to the wide variation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration </strong>– Patients should apply <a class="drug drug_general" data-topicid="10218" href="/z/d/drug information/10218.html" rel="external">podophyllotoxin</a> twice daily for three consecutive days, then withhold use for four consecutive days. This one-week course may be repeated up to four times until warts are no longer visible.</p><p></p><p class="bulletIndent1">The total treatment area should not exceed 10 cm<sup>2</sup>, and the total volume of <a class="drug drug_general" data-topicid="10218" href="/z/d/drug information/10218.html" rel="external">podophyllotoxin</a> should be limited to 0.5 mL per day. The area to which podophyllotoxin is applied should not contain any open lesions or wounds. Podophyllotoxin should be washed off one to four hours after application in order to minimize local irritation. If feasible, the clinician should apply the first treatment to demonstrate the correct sites for application and proper technique [<a href="#rid1">1</a>]. Sexual intercourse should be avoided when podophyllotoxin is on the skin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects </strong>– In clinical trials of <a class="drug drug_general" data-topicid="10218" href="/z/d/drug information/10218.html" rel="external">podophyllotoxin</a> 0.5% solution or gel, local adverse effects were primarily mild or moderate and did not increase during the treatment period. Severe reactions most often occurred during the first two weeks of treatment. Common adverse effects include local pain, inflammation, erosions, burning, or itching. Excessive application may contribute to adverse effects [<a href="#rid34">34</a>]. The most common systemic adverse effect reported during the clinical studies was headache (7 percent).</p><p></p><p class="headingAnchor" id="H1903329670"><span class="h2">Sinecatechins</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9452" href="/z/d/drug information/9452.html" rel="external">Sinecatechins</a> ointment is a partially purified fraction of the water extract of green tea leaves from <em>Camellia sinensis</em> and consists of a proprietary mixture of catechins and other green tea components [<a href="#rid35">35</a>]. Sinecatechins ointment is available in 10% and 15% formulations. Only the 15% ointment is available in the United States. </p><p>The mechanism of action of <a class="drug drug_general" data-topicid="9452" href="/z/d/drug information/9452.html" rel="external">sinecatechins</a> on anogenital warts is not fully understood. Sinecatechins have been found to upregulate apoptosis-associated genes and to modulate and downregulate genes involved in the proinflammatory response to human papillomavirus (HPV) infection [<a href="#rid36">36,37</a>]. They are also antiproliferative, antiangiogenic, and, most importantly, directly antiviral [<a href="#rid38">38</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy </strong>– Efficacy of <a class="drug drug_general" data-topicid="9452" href="/z/d/drug information/9452.html" rel="external">sinecatechins</a> for anogenital warts is supported by randomized trials [<a href="#rid35">35,39-41</a>]. An analysis of combined data from two identical, phase 3, placebo-controlled, randomized trials in which a total of 1005 adults with anogenital warts were randomly assigned to apply sinecatechins 15% ointment, sinecatechins 10% ointment, or placebo three times daily until complete clearance or for up to a maximum of 16 weeks found that 55, 54, and 35 percent of patients, respectively, achieved complete clearance of all warts during treatment [<a href="#rid35">35</a>]. When males were analyzed separately, complete clearance rates were 49, 46, and 29 percent, respectively. Recurrence rates after complete clearance were low during a 12-week follow-up period, occurring in 7 percent of patients in both sinecatechins treatment groups and 6 percent of patients in the placebo group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration </strong>– <a class="drug drug_general" data-topicid="9452" href="/z/d/drug information/9452.html" rel="external">Sinecatechins</a> 10% and 15% ointments are applied three times per day to anogenital warts until complete clearance, for up to a maximum of 16 weeks. Patients should apply an approximately 0.5 cm strand of the ointment to each wart using fingers. The ointment should be dabbed onto warts to ensure complete coverage, leaving a thin layer of the ointment on the warts [<a href="#rid42">42</a>]. Patients should wash their hands before and after application. It is not necessary to wash off the ointment prior to the next treatment.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9452" href="/z/d/drug information/9452.html" rel="external">Sinecatechins</a> ointment may weaken condoms and diaphragms. Sexual contact should be avoided when the ointment is on the skin [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects </strong>– Local skin reactions (eg, erythema) at the treatment site are frequent [<a href="#rid39">39,41</a>]. Treatment should be continued when the severity of the local skin reaction is acceptable.</p><p></p><p class="headingAnchor" id="H2032688637"><span class="h1">FIRST-LINE CLINICIAN-APPLIED THERAPIES</span><span class="headingEndMark"> — </span>First-line clinician-applied therapies include cryotherapy, <a class="drug drug_general" data-topicid="10296" href="/z/d/drug information/10296.html" rel="external">trichloroacetic acid</a> (TCA) and bichloroacetic acid (BCA), excision, electrosurgery, and laser therapy [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H454288779"><span class="h2">Cryotherapy</span><span class="headingEndMark"> — </span>Cryotherapy involves the use of liquid nitrogen to cause tissue damage by formation of ice crystals, leading to disruption of cell membranes and cell death. This treatment can be used for single or multiple anogenital warts and is most effective for small warts [<a href="#rid43">43,44</a>]. Treatment success rates from randomized trials range from 44 to 75 percent [<a href="#rid19">19</a>].</p><p>Liquid nitrogen is typically applied via a spray gun device or a cotton bud, and two freeze-thaw cycles are performed. A small margin of healthy skin (eg, 1 mm) should be included in the treatment area. We typically treat patients every two weeks for up to 6 to 10 weeks. If clearance has not been achieved within 6 to 10 weeks, other treatment should be implemented. (See  <a class="medical medical_review" href="/z/d/html/109151.html" rel="external">"Minor dermatologic procedures", section on 'Cryotherapy (cryosurgery)'</a>.)</p><p>Patients experience local burning and pain during cryotherapy. Potential side effects after treatment include blistering, dyspigmentation, and scarring. Hyperesthesia and hypoesthesia also can occur after cryosurgery but are almost always temporary [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/z/d/html/109151.html" rel="external">"Minor dermatologic procedures", section on 'Adverse outcomes and considerations'</a>.)</p><p class="headingAnchor" id="H3654003169"><span class="h2">Electrosurgery</span><span class="headingEndMark"> — </span>Anogenital warts can be destroyed with electrocautery [<a href="#rid46">46</a>]. After the injection of a local anesthetic, warts are desiccated and are either left to fall off or curetted. Care must be taken to control the depth of electrocautery to minimize scarring. Similar to surgical excision, high clearance rates (94 to 100 percent) have been reported in randomized trials but recurrence is possible [<a href="#rid19">19</a>]. Although these clearance rates are higher than those reported for cryotherapy, electrosurgery is more likely to result in permanent dyspigmentation and scarring.</p><p>Caution is indicated during the treatment of anal warts. Electrosurgery or excisions that injure the anal sphincter can result in anal incontinence, painful defecation, or fistulas [<a href="#rid47">47</a>].</p><p>Risk for transmission of human papillomavirus (HPV) to oral or nasal mucosa of health care workers during electrosurgery or laser treatment of anogenital warts is likely low [<a href="#rid48">48</a>]. However, it is recommended to perform electrosurgery in a well-ventilated room with exhaust ventilation at the treatment site to minimize risk of transmission [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H715847958"><span class="h2">Trichloroacetic acid</span><span class="headingEndMark"> — </span>TCA (where available) is a relatively inexpensive caustic agent that destroys warts through chemical coagulation of protein.</p><p>TCA therapy is best suited for small warts, as its ability to penetrate skin may be limited. Clearance rates reported in randomized trials range from 56 to 81 percent [<a href="#rid19">19</a>]. TCA was less effective than cryotherapy in a trial in which 86 patients with anogenital warts were randomly assigned to once-weekly treatment with either liquid nitrogen applied with a cotton pledget or 95% TCA for up to six treatments [<a href="#rid50">50</a>]. A commercial pharmaceutical formulation of 80% TCA is no longer available in the United States or Canada.</p><p>A small amount of 80 or 90% TCA is applied directly to the warts with a cotton tip applicator and allowed to dry. A white frost becomes visible at the treatment site. A reasonable treatment course for TCA is once-weekly application for three to four weeks or every two weeks for 8 to 10 weeks.</p><p>Disadvantages of TCA include the need for multiple treatment sessions and the occurrence of a burning sensation at the site of application that lasts a few minutes. TCA should be applied carefully only to wart-bearing skin because excessive application can lead to damage to adjacent tissues. The material should be allowed to completely dry (forming a "white frost") before the patient sits up, stands, and walks.</p><p>BCA is similar to TCA and is more typically used in gynecology. Directions for use of TCA and BCA are similar. (See  <a class="medical medical_review" href="/z/d/html/5458.html" rel="external">"Condylomata acuminata (anogenital warts): Treatment of vulvar and vaginal warts", section on 'Trichloroacetic acid and bichloracetic acid'</a>.)</p><p class="headingAnchor" id="H637919855"><span class="h2">Surgical excision</span><span class="headingEndMark"> — </span>Surgical excision is most beneficial for patients who have large (eg, &gt;1 cm), exophytic anogenital warts. A scissor or shave excision can remove most anogenital warts [<a href="#rid51">51</a>]. Excision to the depth of the superficial dermis is generally sufficient [<a href="#rid1">1</a>]. More extensive excisions under general anesthesia may be required to remove extensive or bulky warts [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/5577.html" rel="external">"Skin biopsy techniques", section on 'Shave biopsy'</a>.)</p><p>Disadvantages of surgical excision include the need for local anesthesia and scarring at the excision site. The surgical site may be sore and tender for approximately one to four weeks. Although high success rates for excision (89 to 100 percent) have been reported in randomized trials, recurrences developed in up to one-third of patients [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H274299467"><span class="h2">Laser therapy</span><span class="headingEndMark"> — </span>Carbon dioxide (CO<sub>2</sub>) lasers are the principal lasers used to destroy anogenital warts. Treatment is painful; local or general anesthesia is necessary. Clearance and recurrence rates after CO<sub>2</sub> laser treatment vary widely [<a href="#rid52">52</a>]. A questionnaire-based study of 107 males treated with extensive, cauliflower-like endoanal or perianal warts found that 21 of 25 patients (84 percent) with perianal warts who responded to the questionnaire were cured after a single treatment [<a href="#rid52">52</a>]. However, only 64 patients (60 percent) responded to the questionnaire, and clearance rates as low as 23 percent and recurrence rates as high as 77 percent have been reported [<a href="#rid53">53</a>]. Potential complications include persistent pain, anal fissures, and scarring.</p><p>Other lasers are less frequently used for the treatment of anogenital warts [<a href="#rid54">54</a>]. Most reports of the neodymium-doped yttrium aluminum garnet (Nd:YAG) laser focus on use for urethral warts [<a href="#rid54">54,55</a>]. Data on the use of the pulsed dye laser and thulium laser are limited [<a href="#rid54">54,56,57</a>]. Further study is necessary to confirm the results of an uncontrolled study that found a low rate of relapse for anogenital warts after combination treatment with a CO<sub>2</sub> laser and one to six sessions of photodynamic therapy performed with topical <a class="drug drug_general" data-topicid="9199" href="/z/d/drug information/9199.html" rel="external">aminolevulinic acid</a> and a 635 nm laser [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H2933768821"><span class="h1">SECOND-LINE THERAPY</span><span class="headingEndMark"> — </span>Patients who do not respond to a first-line treatment may benefit from a trial of an alternative first-line treatment or combination treatment. Cryotherapy plus a topical agent is a common initial choice for combination treatment. (See <a class="local">'Combination therapy'</a> above.)</p><p class="headingAnchor" id="H618883751"><span class="h1">OTHER THERAPIES</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9786" href="/z/d/drug information/9786.html" rel="external">Podophyllin resin</a> and topical <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> can be effective for external anogenital warts but are not recommended as first-line treatments because of side effects. </p><p class="headingAnchor" id="H1437714953"><span class="h2">Podophyllin resin</span><span class="headingEndMark"> — </span>Podophyllin is a plant-derived antimitotic agent that disrupts viral activity by inducing local tissue necrosis. <a class="drug drug_general" data-topicid="9786" href="/z/d/drug information/9786.html" rel="external">Podophyllin resin</a> is <strong>not</strong> recommended for the treatment of anogenital warts because of the availability of more efficacious and safer therapies [<a href="#rid1">1</a>].</p><p>Head-to-head studies demonstrate that <a class="drug drug_general" data-topicid="9786" href="/z/d/drug information/9786.html" rel="external">podophyllin</a> is a suboptimal treatment compared with <a class="drug drug_general" data-topicid="10218" href="/z/d/drug information/10218.html" rel="external">podophyllotoxin</a>. In a randomized trial that compared four weeks of treatment with patient-applied podophyllotoxin 0.5% solution (three consecutive days per week), patient-applied podophyllotoxin 0.15% cream (three consecutive days per week), and clinician-applied 25% podophyllin (twice weekly) for the treatment of anogenital warts, podophyllotoxin demonstrated greater efficacy and cost-effectiveness than podophyllin [<a href="#rid59">59</a>].</p><p>Common local side effects of <a class="drug drug_general" data-topicid="9786" href="/z/d/drug information/9786.html" rel="external">podophyllin</a> are application site reactions (slight stinging, pain, numbness, tingling, or burning). Podophyllin can be systemically absorbed; the toxicity of the drug increases when applied to areas greater than 110 mm<sup>2</sup> or to skin surfaces that favor systemic absorption. Potential side effects include fever, mild gastrointestinal distress, paralytic ileus, bone-marrow suppression, polyneuritis, paresthesias, coma, and death. To minimize side effects, a thin layer of podophyllin should be applied to warts and allowed to air-dry completely. Over-application or failure to air-dry can spread the podophyllin and increase the rate of local reactions.</p><p class="headingAnchor" id="H3605591484"><span class="h2">Topical fluorouracil</span><span class="headingEndMark"> — </span>A systematic review of randomized trials found treatment with topical <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> more effective than placebo or no treatment for anogenital warts in nonimmunocompromised adults (relative risk for cure 0.39, 95% CI 0.23-0.67) [<a href="#rid60">60</a>]. However, high-quality, randomized trials evaluating fluorouracil therapy are lacking, and the use of topical fluorouracil is limited by potential adverse effects, such as local inflammation, pain, burning, and ulceration.</p><p class="headingAnchor" id="H3927358240"><span class="h2">Cantharidin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8838" href="/z/d/drug information/8838.html" rel="external">Cantharidin</a> is a terpenoid vesicant produced by blister beetles commonly used for molluscum contagiosum and common warts. Cantharidin acts as an acantholytic blistering agent that creates a blister between the dermis and the epidermis. A trial in which 12 females with nonmucosal genital warts were randomly assigned to treatment with either <a class="drug drug_general" data-topicid="10296" href="/z/d/drug information/10296.html" rel="external">trichloroacetic acid</a> (TCA) or cantharidin found a nonstatistically significant trend favoring cantharidin treatment over TCA [<a href="#rid61">61</a>]. All six patients in the cantharidin group had complete clearance of warts versus four of six (66 percent) in the TCA group. Additional study is necessary to clarify the efficacy of cantharidin for CA.</p><p class="headingAnchor" id="H582645597"><span class="h1">REFRACTORY DISEASE</span><span class="headingEndMark"> — </span>Patients with anogenital warts that cannot be eradicated with first-line therapies or combinations of first-line therapies may require use of alternative treatments. (See <a class="local">'First-line patient-applied therapies'</a> above and <a class="local">'First-line clinician-applied therapies'</a> above and <a class="local">'Second-line therapy'</a> above.)</p><p>There are multiple reports of positive responses of anogenital warts to topical or intralesional <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">cidofovir</a>, a monophosphate nucleotide analogue that competitively inhibits viral DNA polymerase [<a href="#rid62">62-69</a>]. In a phase 2, randomized trial in which 30 patients were randomly assigned to cidofovir 1% gel or placebo, 9 of 19 patients (47 percent) in the cidofovir group had a complete response compared with no patients in the placebo group [<a href="#rid63">63</a>]. In addition, cidofovir 1% cream was more effective than a vehicle cream for anogenital warts in a single-blind randomized, crossover trial with 12 human immunodeficiency virus (HIV)-infected patients [<a href="#rid64">64</a>]. In an open randomized trial, combination treatment with electrocautery and cidofovir 1% gel was more effective than monotherapy with either agent in HIV-infected patients [<a href="#rid70">70</a>]. Topical cidofovir is obtained through compounding pharmacies. Cost and insurance coverage can be limiting factors.</p><p>Intralesional interferon is infrequently used for the treatment of anogenital warts [<a href="#rid71">71</a>]. Interferon injections are expensive and most useful in combination with other treatments [<a href="#rid72">72</a>].</p><p>Rarely, systemic treatments are used for difficult cases. Benefit has been reported with low-dose oral <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> [<a href="#rid73">73,74</a>].The mechanism of cyclophosphamide may involve selective targeting of regulatory T cells, thereby enhancing the function of human papillomavirus (HPV)-specific T cells and natural killer cells, leading to clearance of HPV infection. There are conflicting data on the efficacy of oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> [<a href="#rid75">75-78</a>]. Treatment with systemic <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> and radiation was associated with improvement in anogenital warts with associated squamous cell carcinoma in an immunosuppressed adolescent [<a href="#rid79">79</a>]. Case reports describe successful use of hyperthermia [<a href="#rid80">80</a>] and external beam radiotherapy [<a href="#rid81">81</a>] for extensive anogenital warts. There is no reliable evidence to support use of systemic interferon after ablative treatment of CA [<a href="#rid82">82</a>].</p><p>Treatment of anogenital warts with any HPV vaccine formulation cannot be recommended. Although resolution of perianal warts was reported in a patient who received the quadrivalent HPV vaccine following unsuccessful treatment with <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a> [<a href="#rid83">83</a>], in a series of six patients vaccinated after ablation of anogenital warts with electrocautery, warts recurred in all patients [<a href="#rid84">84</a>]. (See  <a class="medical medical_review" href="/z/d/html/8325.html" rel="external">"Human papillomavirus vaccination"</a>.)</p><p class="headingAnchor" id="H1446420768"><span class="h1">EMERGING THERAPIES</span><span class="headingEndMark"> — </span>Benefit of topical sodium nitrate with citric acid [<a href="#rid85">85</a>], <em>Mycobacterium w</em> vaccine [<a href="#rid86">86</a>], topical nitric-zinc complex [<a href="#rid87">87</a>], virus-like particle immunotherapy [<a href="#rid88">88</a>], glycyrrhizinic acid plus an immunostimulant food supplement [<a href="#rid89">89</a>], and photodynamic therapy [<a href="#rid90">90-94</a>] has been documented in clinical studies, and resolution of recalcitrant giant CA after combination therapy with <em>Mycobacterium indicus pranii </em>immunotherapy and <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> is documented in a case report [<a href="#rid95">95</a>]. Further study is necessary prior to recommendations for the use of these treatments.</p><p class="headingAnchor" id="H1957908550"><span class="h1">INDICATIONS FOR REFERRAL</span><span class="headingEndMark"> — </span>Referral to a specialist experienced in the treatment of anogenital warts (eg, dermatologist, urologist, or colorectal surgeon) is appropriate for patients who are immunosuppressed or who have treatment-refractory anogenital warts. Patients with large, bulky perianal or genital warts that may require extensive surgical removal should be referred to a colorectal surgeon or urologist. In addition, for patients with perianal warts, we suggest performing or referring for anoscopy to evaluate for intra-anal warts. Intra-anal and intraurethral warts are typically managed by colorectal surgeons and urologists, respectively. (See  <a class="medical medical_review" href="/z/d/html/99981.html" rel="external">"Condylomata acuminata (anogenital warts) in adults: Epidemiology, pathogenesis, clinical features, and diagnosis", section on 'Internal involvement'</a>.)</p><p class="headingAnchor" id="H1757009848"><span class="h1">PROGNOSIS AND FOLLOW-UP</span><span class="headingEndMark"> — </span>Recurrences may appear soon after treatment or after months or years. Factors that may contribute to recurrences after treatment include persistent subclinical infection, repeat infection, and immunosuppression.</p><p>The timing of follow-up after the start of treatment depends on the mode of treatment. For topical patient-applied therapies, patients should be re-evaluated after the completion of a treatment course. After clinician-administered destructive therapies, we typically re-examine patients after two weeks to evaluate the response and assess for proper healing.</p><p>Patients should be instructed to return for clinical evaluation if new warts develop after treatment.</p><p class="headingAnchor" id="H449358813"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Sexual activity is the primary risk factor for acquisition of human papillomavirus (HPV) infection and the development of anogenital warts. The optimal way to prevent anogenital warts is vaccination prior to the onset of sexual activity. In addition, limiting the number of lifetime sexual partners and delaying the age of first intercourse reduce the risk of HPV infection [<a href="#rid96">96</a>]. Vaccination against HPV and the prevention of sexually transmitted infections are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/8325.html" rel="external">"Human papillomavirus vaccination"</a> and  <a class="medical medical_review" href="/z/d/html/7595.html" rel="external">"Prevention of sexually transmitted infections"</a>.)</p><p class="headingAnchor" id="H3794696160"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111582.html" rel="external">"Society guideline links: Sexually transmitted infections"</a>.)</p><p class="headingAnchor" id="H2980261020"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15377.html" rel="external">"Patient education: Anogenital warts (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/15743.html" rel="external">"Patient education: Human papillomavirus (HPV) vaccine (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/4022.html" rel="external">"Patient education: Human papillomavirus (HPV) vaccine (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/8409.html" rel="external">"Patient education: Genital warts in women (Beyond the Basics)"</a>)</p><p></p><p>Additional resources for information on HPV infection and anogenital warts include the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fstd%2Fhpv%2F&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLOxtJPrfMYPNhT2h2TCRZ%2FlPNXzW6cBX7e37y0N4VOz7&amp;TOPIC_ID=99984" target="_blank">Centers for Disease Control and Prevention (CDC)</a> and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ashasexualhealth.org%2Fhuman_papilloma_virus%2F&amp;token=47eFe7vPDG7BKPitJu6dnDNv5oNpPOY9wxTzEEV599fzf2HwigP2wy5PoGfXAfcvpQdzONmSvZ3YRb3L1Ym4nQ%3D%3D&amp;TOPIC_ID=99984" target="_blank">American Sexual Health Association (ASHA)</a>.</p><p class="headingAnchor" id="H4228935218"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– Condylomata acuminata (CA), also known as anogenital warts, are a manifestation of anogenital human papillomavirus (HPV) infection  (<a class="graphic graphic_picture graphicRef108140 graphicRef60946 graphicRef51759 graphicRef108145 graphicRef108144 graphicRef108141 graphicRef108146 graphicRef108147" href="/z/d/graphic/108140.html" rel="external">picture 1A-H</a>). Anogenital warts are almost always acquired through sexual activity. (See  <a class="medical medical_review" href="/z/d/html/99981.html" rel="external">"Condylomata acuminata (anogenital warts) in adults: Epidemiology, pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient counseling </strong>– A diagnosis of CA can have negative psychosocial effects. Patients may benefit from education on HPV infection and CA. Clinicians should offer resources for psychologic support when needed. (See <a class="local">'Patient counseling'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Decision to treat </strong>– Although CA may spontaneously resolve, resolution may take months and is unpredictable. Treatment should be offered to all patients. Most patients elect to proceed with treatment. (See <a class="local">'Indications for treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selection of initial treatment </strong>– There is no single best approach to the treatment of anogenital warts. Treatment selection should be individualized and based upon consideration of factors such as the extent of disease, patient preference, cost, adverse effects, and treatment availability. The major treatment options for CA can be divided into patient-applied and clinician-administered therapies (see <a class="local">'Treatment options'</a> above and <a class="local">'Treatment selection'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patient-applied therapy </strong>– For patient-applied therapy, we recommend use of <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a>, <a class="drug drug_general" data-topicid="10218" href="/z/d/drug information/10218.html" rel="external">podophyllotoxin</a>, or <a class="drug drug_general" data-topicid="9452" href="/z/d/drug information/9452.html" rel="external">sinecatechins</a> (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). Patients treated with patient-applied therapies should be able to identify and reach all anogenital warts and should be willing to adhere to several weeks or longer of treatment. (See <a class="local">'Treatment selection'</a> above and <a class="local">'First-line patient-applied therapies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinician-applied therapy </strong>– First-line clinician-administered therapies include cryotherapy, <a class="drug drug_general" data-topicid="10296" href="/z/d/drug information/10296.html" rel="external">trichloroacetic acid</a> (TCA), surgical excision, electrosurgery, and carbon dioxide laser therapy. We suggest <strong>not</strong> treating anogenital warts with <a class="drug drug_general" data-topicid="9786" href="/z/d/drug information/9786.html" rel="external">podophyllin resin</a> based upon the availability of safer and more effective therapies (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Treatment selection'</a> above and <a class="local">'First-line clinician-applied therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Failure of initial treatment </strong>– Patients who fail to respond to an initial first-line therapy may benefit from switching to an alternative first-line intervention or combination treatment. A common option for combination therapy is the use of a patient-applied topical therapy in-between treatment sessions for a clinician-administered treatment. (See <a class="local">'Second-line therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention </strong>– Sexual activity is the primary risk factor for the development of CA. Vaccination against HPV can prevent the acquisition of CA. (See <a class="local">'Prevention'</a> above and  <a class="medical medical_review" href="/z/d/html/8325.html" rel="external">"Human papillomavirus vaccination"</a>.)</p><p></p><p class="headingAnchor" id="H3089718152"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Noah Scheinfeld, MD (deceased), who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.</a></li><li><a class="nounderline abstract_t">Handsfield HH. Clinical presentation and natural course of anogenital warts. Am J Med 1997; 102:16.</a></li><li><a class="nounderline abstract_t">Yanofsky VR, Patel RV, Goldenberg G. Genital warts: a comprehensive review. J Clin Aesthet Dermatol 2012; 5:25.</a></li><li><a class="nounderline abstract_t">Gunter J. Genital and perianal warts: new treatment opportunities for human papillomavirus infection. Am J Obstet Gynecol 2003; 189:S3.</a></li><li><a class="nounderline abstract_t">Vender R, Bourcier M, Bhatia N, Lynde C. Therapeutic options for external genital warts. J Cutan Med Surg 2013; 17 Suppl 2:S61.</a></li><li><a class="nounderline abstract_t">Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 2002; 29:725.</a></li><li><a class="nounderline abstract_t">Sénécal M, Brisson M, Maunsell E, et al. Loss of quality of life associated with genital warts: baseline analyses from a prospective study. Sex Transm Infect 2011; 87:209.</a></li><li><a class="nounderline abstract_t">Dominiak-Felden G, Cohet C, Atrux-Tallau S, et al. Impact of human papillomavirus-related genital diseases on quality of life and psychosocial wellbeing: results of an observational, health-related quality of life study in the UK. BMC Public Health 2013; 13:1065.</a></li><li><a class="nounderline abstract_t">Qi SZ, Wang SM, Shi JF, et al. Human papillomavirus-related psychosocial impact of patients with genital warts in China: a hospital-based cross-sectional study. BMC Public Health 2014; 14:739.</a></li><li><a class="nounderline abstract_t">Newton DC, McCabe M. Effects of sexually transmitted infection status, relationship status, and disclosure status on sexual self-concept. J Sex Res 2008; 45:187.</a></li><li><a class="nounderline abstract_t">Silvera RJ, Smith CK, Swedish KA, Goldstone SE. Anal condyloma treatment and recurrence in HIV-negative men who have sex with men. Dis Colon Rectum 2014; 57:752.</a></li><li><a class="nounderline abstract_t">Juhl ME, Seferovic V, Antonijevic S, Krunic A. Combined treatment of anogenital HPV infection with cryodestruction, podophyllin 25% and post-ablation immunomodulation with sinecatechins 15% ointment - a retrospective analysis. Int J STD AIDS 2016; 27:1071.</a></li><li><a class="nounderline abstract_t">On SC, Linkner RV, Haddican M, et al. A single-blinded randomized controlled study to assess the efficacy of twice daily application of sinecatechins 15% ointment when used sequentially with cryotherapy in the treatment of external genital warts. J Drugs Dermatol 2014; 13:1400.</a></li><li><a class="nounderline abstract_t">Gilson RJ, Ross J, Maw R, et al. A multicentre, randomised, double-blind, placebo controlled study of cryotherapy versus cryotherapy and podophyllotoxin cream as treatment for external anogenital warts. Sex Transm Infect 2009; 85:514.</a></li><li><a class="nounderline abstract_t">O'Mahony C, Gomberg M, Skerlev M, et al. Position statement for the diagnosis and management of anogenital warts. J Eur Acad Dermatol Venereol 2019; 33:1006.</a></li><li><a class="nounderline abstract_t">Gilson R, Nugent D, Werner RN, et al. 2019 IUSTI-Europe guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol 2020; 34:1644.</a></li><li><a class="nounderline abstract_t">Arany I, Tyring SK, Brysk MM, et al. Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital warts. Antimicrob Agents Chemother 2000; 44:1869.</a></li><li><a class="nounderline abstract_t">Grillo-Ardila CF, Angel-Müller E, Salazar-Díaz LC, et al. Imiquimod for anogenital warts in non-immunocompromised adults. Cochrane Database Syst Rev 2014; :CD010389.</a></li><li><a class="nounderline abstract_t">Lacey CJ, Woodhall SC, Wikstrom A, Ross J. 2012 European guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol 2013; 27:e263.</a></li><li><a class="nounderline abstract_t">Komericki P, Akkilic-Materna M, Strimitzer T, Aberer W. Efficacy and safety of imiquimod versus podophyllotoxin in the treatment of anogenital warts. Sex Transm Dis 2011; 38:216.</a></li><li class="breakAll">Zyclara (imiquimod) cream, 3.75%. US FDA approved product information; Bristol, TN: Graceway Pharmaceuticals; March 2011. www.accessdata.fda.gov/drugsatfda_docs/label/2011/201153s000,022483s001lbl.pdf (Accessed on April 08, 2011).</li><li><a class="nounderline abstract_t">Rosen T, Nelson A, Ault K. Imiquimod cream 2.5% and 3.75% applied once daily to treat external genital warts in men. Cutis 2015; 96:277.</a></li><li><a class="nounderline abstract_t">Baker DA, Ferris DG, Martens MG, et al. Imiquimod 3.75% cream applied daily to treat anogenital warts: combined results from women in two randomized, placebo-controlled studies. Infect Dis Obstet Gynecol 2011; 2011:806105.</a></li><li class="breakAll">Aldara (imiquimod) Cream, 5%. US FDA approved product information; Bristol, TN: Graceway Pharmaceuticals; October 2010. www.accessdata.fda.gov/drugsatfda_docs/label/2010/020723s022lbl.pdf (Accessed on June 02, 2016).</li><li><a class="nounderline abstract_t">Stefanaki C, Nicolaidou E, Hadjivassiliou M, et al. Imiquimod-induced vitiligo in a patient with genital warts. J Eur Acad Dermatol Venereol 2006; 20:755.</a></li><li><a class="nounderline abstract_t">Li W, Xin H, Ge L, et al. Induction of vitiligo after imiquimod treatment of condylomata acuminata. BMC Infect Dis 2014; 14:329.</a></li><li><a class="nounderline abstract_t">Brown T, Zirvi M, Cotsarelis G, Gelfand JM. Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts. J Am Acad Dermatol 2005; 52:715.</a></li><li><a class="nounderline abstract_t">Vidal NY, Farah RS, Wanat KA. Dramatic saxophone penis as a result of topical imiquimod use. JAMA Dermatol 2014; 150:1370.</a></li><li><a class="nounderline abstract_t">Cantisani C, Lazic T, Richetta AG, et al. Imiquimod 5% cream use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov 2012; 6:65.</a></li><li><a class="nounderline abstract_t">Tyring S, Edwards L, Cherry LK, et al. Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts. Arch Dermatol 1998; 134:33.</a></li><li><a class="nounderline abstract_t">Greenberg MD, Rutledge LH, Reid R, et al. A double-blind, randomized trial of 0.5% podofilox and placebo for the treatment of genital warts in women. Obstet Gynecol 1991; 77:735.</a></li><li><a class="nounderline abstract_t">Kirby P, Dunne A, King DH, Corey L. Double-blind randomized clinical trial of self-administered podofilox solution versus vehicle in the treatment of genital warts. Am J Med 1990; 88:465.</a></li><li><a class="nounderline abstract_t">Beutner KR, Conant MA, Friedman-Kien AE, et al. Patient-applied podofilox for treatment of genital warts. Lancet 1989; 1:831.</a></li><li class="breakAll">Condylox [package insert]. Parsippany, NJ: Watson Pharma; Revised March 2011.</li><li><a class="nounderline abstract_t">Tatti S, Stockfleth E, Beutner KR, et al. Polyphenon E: a new treatment for external anogenital warts. Br J Dermatol 2010; 162:176.</a></li><li><a class="nounderline abstract_t">Doan HQ, Nguyen HP, Rady P, Tyring SK. Expression patterns of immune-associated genes in external genital and perianal warts treated with sinecatechins. Viral Immunol 2015; 28:236.</a></li><li><a class="nounderline abstract_t">Nguyen HP, Doan HQ, Brunell DJ, et al. Apoptotic gene expression in sinecatechins-treated external genital and perianal warts. Viral Immunol 2014; 27:556.</a></li><li><a class="nounderline abstract_t">Rosen T. Green tea catechins: biologic properties, proposed mechanisms of action, and clinical implications. J Drugs Dermatol 2012; 11:e55.</a></li><li><a class="nounderline abstract_t">Stockfleth E, Beti H, Orasan R, et al. Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial. Br J Dermatol 2008; 158:1329.</a></li><li><a class="nounderline abstract_t">Gross G, Meyer KG, Pres H, et al. A randomized, double-blind, four-arm parallel-group, placebo-controlled Phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon E in the treatment of external genital warts. J Eur Acad Dermatol Venereol 2007; 21:1404.</a></li><li><a class="nounderline abstract_t">Tatti S, Swinehart JM, Thielert C, et al. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol 2008; 111:1371.</a></li><li class="breakAll">Veregen (sinecatechins) Ointment, 15%. US FDA approved product information; Fairfield, NJ: Bradley Pharmaceuticals; December 2007. www.accessdata.fda.gov/drugsatfda_docs/label/2007/021902s002lbl.pdf (Accessed on May 27, 2016).</li><li><a class="nounderline abstract_t">Damstra RJ, van Vloten WA. Cryotherapy in the treatment of condylomata acuminata: a controlled study of 64 patients. J Dermatol Surg Oncol 1991; 17:273.</a></li><li><a class="nounderline abstract_t">Gross G. [Clinical aspects and therapy of anogenital warts and papillomavirus-associated lesions]. Hautarzt 2001; 52:6.</a></li><li><a class="nounderline abstract_t">Zimmerman EE, Crawford P. Cutaneous cryosurgery. Am Fam Physician 2012; 86:1118.</a></li><li><a class="nounderline abstract_t">Mahrle G, Alexander W. Surgical treatment of recalcitrant warts. J Dermatol Surg Oncol 1983; 9:445.</a></li><li><a class="nounderline abstract_t">Ammori BJ, Ausobsky JR. Electrocoagulation of perianal warts: a word of caution. Dig Surg 2000; 17:296.</a></li><li><a class="nounderline abstract_t">Kofoed K, Norrbom C, Forslund O, et al. Low prevalence of oral and nasal human papillomavirus in employees performing CO2-laser evaporation of genital warts or loop electrode excision procedure of cervical dysplasia. Acta Derm Venereol 2015; 95:173.</a></li><li><a class="nounderline abstract_t">Park IU, Introcaso C, Dunne EF. Human Papillomavirus and Genital Warts: A Review of the Evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. Clin Infect Dis 2015; 61 Suppl 8:S849.</a></li><li><a class="nounderline abstract_t">Abdullah AN, Walzman M, Wade A. Treatment of external genital warts comparing cryotherapy (liquid nitrogen) and trichloroacetic acid. Sex Transm Dis 1993; 20:344.</a></li><li><a class="nounderline abstract_t">Khawaja HT. Podophyllin versus scissor excision in the treatment of perianal condylomata acuminata: a prospective study. Br J Surg 1989; 76:1067.</a></li><li><a class="nounderline abstract_t">Carrozza PM, Merlani GM, Burg G, Hafner J. CO(2) laser surgery for extensive, cauliflower-like anogenital condylomata acuminata: retrospective long-term study on 19 HIV-positive and 45 HIV-negative men. Dermatology 2002; 205:255.</a></li><li><a class="nounderline abstract_t">Scheinfeld N, Lehman DS. An evidence-based review of medical and surgical treatments of genital warts. Dermatol Online J 2006; 12:5.</a></li><li><a class="nounderline abstract_t">Blokker RS, Lock TM, de Boorder T. Comparing thulium laser and Nd:YAG laser in the treatment of genital and urethral condylomata acuminata in male patients. Lasers Surg Med 2013; 45:582.</a></li><li><a class="nounderline abstract_t">Volz LR, Carpiniello VL, Malloy TR. Laser treatment of urethral condyloma: a five-year experience. Urology 1994; 43:81.</a></li><li><a class="nounderline abstract_t">Komericki P, Akkilic M, Kopera D. Pulsed dye laser treatment of genital warts. Lasers Surg Med 2006; 38:273.</a></li><li><a class="nounderline abstract_t">Tuncel A, Görgü M, Ayhan M, et al. Treatment of anogenital warts by pulsed dye laser. Dermatol Surg 2002; 28:350.</a></li><li><a class="nounderline abstract_t">Huang J, Zeng Q, Zuo C, et al. The combination of CO2 laser vaporation and photodynamic therapy in treatment of condylomata acuminata. Photodiagnosis Photodyn Ther 2014; 11:130.</a></li><li><a class="nounderline abstract_t">Lacey CJ, Goodall RL, Tennvall GR, et al. Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts. Sex Transm Infect 2003; 79:270.</a></li><li><a class="nounderline abstract_t">Batista CS, Atallah AN, Saconato H, da Silva EM. 5-FU for genital warts in non-immunocompromised individuals. Cochrane Database Syst Rev 2010; :CD006562.</a></li><li><a class="nounderline abstract_t">Recanati MA, Kramer KJ, Maggio JJ, Chao CR. Cantharidin is Superior to Trichloroacetic Acid for the Treatment of Non-mucosal Genital Warts: A Pilot Randomized Controlled Trial. Clin Exp Obstet Gynecol 2018; 45:383.</a></li><li><a class="nounderline abstract_t">Orlando G, Fasolo MM, Beretta R, et al. Intralesional or topical cidofovir (HPMPC, VISTIDE) for the treatment of recurrent genital warts in HIV-1-infected patients. AIDS 1999; 13:1978.</a></li><li><a class="nounderline abstract_t">Snoeck R, Bossens M, Parent D, et al. Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clin Infect Dis 2001; 33:597.</a></li><li><a class="nounderline abstract_t">Matteelli A, Beltrame A, Graifemberghi S, et al. Efficacy and tolerability of topical 1% cidofovir cream for the treatment of external anogenital warts in HIV-infected persons. Sex Transm Dis 2001; 28:343.</a></li><li><a class="nounderline abstract_t">Snoeck R, Van Ranst M, Andrei G, et al. Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue. N Engl J Med 1995; 333:943.</a></li><li><a class="nounderline abstract_t">Martinelli C, Farese A, Mistro AD, et al. Resolution of recurrent perianal condylomata acuminata by topical cidofovir in patients with HIV infection. J Eur Acad Dermatol Venereol 2001; 15:568.</a></li><li><a class="nounderline abstract_t">Stragier I, Snoeck R, De Clercq E, et al. Local treatment of HPV-induced skin lesions by Cidofovir. J Med Virol 2002; 67:241.</a></li><li><a class="nounderline abstract_t">Hengge UR, Tietze G. Successful treatment of recalcitrant condyloma with topical cidofovir. Sex Transm Infect 2000; 76:143.</a></li><li><a class="nounderline abstract_t">Coremans G, Margaritis V, Snoeck R, et al. Topical cidofovir (HPMPC) is an effective adjuvant to surgical treatment of anogenital condylomata acuminata. Dis Colon Rectum 2003; 46:1103.</a></li><li><a class="nounderline abstract_t">Orlando G, Fasolo MM, Beretta R, et al. Combined surgery and cidofovir is an effective treatment for genital warts in HIV-infected patients. AIDS 2002; 16:447.</a></li><li><a class="nounderline abstract_t">Yang J, Pu YG, Zeng ZM, et al. Interferon for the treatment of genital warts: a systematic review. BMC Infect Dis 2009; 9:156.</a></li><li><a class="nounderline abstract_t">Handley JM, Horner T, Maw RD, et al. Subcutaneous interferon alpha 2a combined with cryotherapy vs cryotherapy alone in the treatment of primary anogenital warts: a randomised observer blind placebo controlled study. Genitourin Med 1991; 67:297.</a></li><li><a class="nounderline abstract_t">Zhao J, Zeng W, Cao Y, et al. Immunotherapy of HPV infection-caused genital warts using low dose cyclophosphamide. Expert Rev Clin Immunol 2014; 10:791.</a></li><li><a class="nounderline abstract_t">Zhang Y, Duan Y, Zhao J, et al. Low-dose oral cyclophosphamide therapy is effective for condylomata acuminata. Chin Med J (Engl) 2013; 126:3198.</a></li><li><a class="nounderline abstract_t">Pasmatzi E, Kapranos N, Monastirli A, et al. Large benign condyloma acuminatum: successful treatment with isotretinoin and interferon alpha. Acta Derm Venereol 2012; 92:249.</a></li><li><a class="nounderline abstract_t">Yew YW, Pan JY. Complete remission of recalcitrant genital warts with a combination approach of surgical debulking and oral isotretinoin in a patient with systemic lupus erythematosus. Dermatol Ther 2014; 27:79.</a></li><li><a class="nounderline abstract_t">Olsen EA, Kelly FF, Vollmer RT, et al. Comparative study of systemic interferon alfa-nl and isotretinoin in the treatment of resistant condylomata acuminata. J Am Acad Dermatol 1989; 20:1023.</a></li><li><a class="nounderline abstract_t">Cardamakis EK, Kotoulas IG, Dimopoulos DP, et al. Comparative study of systemic interferon alfa-2a with oral isotretinoin and oral isotretinoin alone in the treatment of recurrent condylomata accuminata. Arch Gynecol Obstet 1996; 258:35.</a></li><li><a class="nounderline abstract_t">Paul S, Cheng CE, Kroshinsky D. Combination Systemic Fluorouracil and Radiation for the Treatment of Recalcitrant Condyloma with Associated Squamous Cell Carcinoma in an Immunocompromised 15-Year-Old Girl. Pediatr Dermatol 2015; 32:e148.</a></li><li><a class="nounderline abstract_t">Huo W, Li GH, Qi RQ, et al. Clinical and immunologic results of local hyperthermia at 44 °C for extensive genital warts in patients with diabetes mellitus. Int J Hyperthermia 2013; 29:17.</a></li><li><a class="nounderline abstract_t">Dhadda AS, Anand A, Boynton C, Chan S. External beam radiotherapy for extensive genital condyloma acuminate: a role in selected patients? Clin Oncol (R Coll Radiol) 2008; 20:91.</a></li><li><a class="nounderline abstract_t">Westfechtel L, Werner RN, Dressler C, et al. Adjuvant treatment of anogenital warts with systemic interferon: a systematic review and meta-analysis. Sex Transm Infect 2018; 94:21.</a></li><li><a class="nounderline abstract_t">Lee HJ, Kim JK, Kim DH, Yoon MS. Condyloma accuminatum treated with recombinant quadrivalent human papillomavirus vaccine (types 6, 11, 16, 18). J Am Acad Dermatol 2011; 64:e130.</a></li><li><a class="nounderline abstract_t">Kreuter A, Wieland U. Lack of efficacy in treating condyloma acuminata and preventing recurrences with the recombinant quadrivalent human papillomavirus vaccine in a case series of immunocompetent patients. J Am Acad Dermatol 2013; 68:179.</a></li><li><a class="nounderline abstract_t">Ormerod AD, van Voorst Vader PC, Majewski S, et al. Evaluation of the Efficacy, Safety, and Tolerability of 3 Dose Regimens of Topical Sodium Nitrite With Citric Acid in Patients With Anogenital Warts: A Randomized Clinical Trial. JAMA Dermatol 2015; 151:854.</a></li><li><a class="nounderline abstract_t">Kumar P, Dar L, Saldiwal S, et al. Intralesional injection of Mycobacterium w vaccine vs imiquimod, 5%, cream in patients with anogenital warts: a randomized clinical trial. JAMA Dermatol 2014; 150:1072.</a></li><li><a class="nounderline abstract_t">Cusini M, Micali G, Lacarrubba F, et al. Efficacy and tolerability of nitric-zinc complex in the treatment of external genital warts and "difficult-to-treat" warts: a "proof of concept", prospective, multicentre, open study. G Ital Dermatol Venereol 2015; 150:643.</a></li><li><a class="nounderline abstract_t">Jardine D, Lu J, Pang J, et al. A randomized trial of immunotherapy for persistent genital warts. Hum Vaccin Immunother 2012; 8:623.</a></li><li><a class="nounderline abstract_t">Domínguez Gómez J, Simón RD, Abreu Daniel A, Zelenkova H. Effectiveness of glycyrrhizinic Acid (glizigen) and an immunostimulant (viusid) to treat anogenital warts. ISRN Dermatol 2012; 2012:863692.</a></li><li><a class="nounderline abstract_t">Ying Z, Li X, Dang H. 5-aminolevulinic acid-based photodynamic therapy for the treatment of condylomata acuminata in Chinese patients: a meta-analysis. Photodermatol Photoimmunol Photomed 2013; 29:149.</a></li><li><a class="nounderline abstract_t">Shi H, Zhang X, Ma C, et al. Clinical analysis of five methods used to treat condylomata acuminata. Dermatology 2013; 227:338.</a></li><li><a class="nounderline abstract_t">Mi X, Chai W, Zheng H, et al. A randomized clinical comparative study of cryotherapy plus photodynamic therapy vs. cryotherapy in the treatment of multiple condylomata acuminata. Photodermatol Photoimmunol Photomed 2011; 27:176.</a></li><li><a class="nounderline abstract_t">Xie J, Ao C, Li J, et al. 5-aminolevulinic acid photodynamic therapy for condyloma acuminatum of urethral meatus. J Dermatolog Treat 2019; 30:714.</a></li><li><a class="nounderline abstract_t">Tu P, Zhang H, Zheng H, et al. 5-Aminolevulinic photodynamic therapy versus carbon dioxide laser therapy for small genital warts: A multicenter, randomized, open-label trial. J Am Acad Dermatol 2021; 84:779.</a></li><li><a class="nounderline abstract_t">Khullar G, Narang T, De D, et al. Recalcitrant giant condyloma acuminatum treated successfully with a novel combination of Mycobacterium indicus pranii immunotherapy and acitretin. Int J STD AIDS 2017; 28:1155.</a></li><li><a class="nounderline abstract_t">Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008; 26 Suppl 10:K1.</a></li></ol></div><div id="topicVersionRevision">Topic 99984 Version 13.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Sexually Transmitted Infections Treatment Guidelines, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9217658" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical presentation and natural course of anogenital warts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22768354" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Genital warts: a comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14532897" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Genital and perianal warts: new treatment opportunities for human papillomavirus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24388560" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Therapeutic options for external genital warts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12438912" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21335602" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Loss of quality of life associated with genital warts: baseline analyses from a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24215264" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Impact of human papillomavirus-related genital diseases on quality of life and psychosocial wellbeing: results of an observational, health-related quality of life study in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25048000" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Human papillomavirus-related psychosocial impact of patients with genital warts in China: a hospital-based cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18569539" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Effects of sexually transmitted infection status, relationship status, and disclosure status on sexual self-concept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24807601" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Anal condyloma treatment and recurrence in HIV-negative men who have sex with men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26404110" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Combined treatment of anogenital HPV infection with cryodestruction, podophyllin 25% and post-ablation immunomodulation with sinecatechins 15% ointment - a retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25607709" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A single-blinded randomized controlled study to assess the efficacy of twice daily application of sinecatechins 15% ointment when used sequentially with cryotherapy in the treatment of external genital warts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19700413" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A multicentre, randomised, double-blind, placebo controlled study of cryotherapy versus cryotherapy and podophyllotoxin cream as treatment for external anogenital warts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30968980" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Position statement for the diagnosis and management of anogenital warts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32735077" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : 2019 IUSTI-Europe guideline for the management of anogenital warts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10858346" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital warts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25362229" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Imiquimod for anogenital warts in non-immunocompromised adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22409368" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : 2012 European guideline for the management of anogenital warts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20938374" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Efficacy and safety of imiquimod versus podophyllotoxin in the treatment of anogenital warts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20938374" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Efficacy and safety of imiquimod versus podophyllotoxin in the treatment of anogenital warts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26682290" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Imiquimod cream 2.5% and 3.75% applied once daily to treat external genital warts in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21876641" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Imiquimod 3.75% cream applied daily to treat anogenital warts: combined results from women in two randomized, placebo-controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21876641" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Imiquimod 3.75% cream applied daily to treat anogenital warts: combined results from women in two randomized, placebo-controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16836520" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Imiquimod-induced vitiligo in a patient with genital warts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24928346" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Induction of vitiligo after imiquimod treatment of condylomata acuminata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15793538" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25207721" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Dramatic saxophone penis as a result of topical imiquimod use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22185454" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Imiquimod 5% cream use in dermatology, side effects and recent patents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9449907" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2014088" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A double-blind, randomized trial of 0.5% podofilox and placebo for the treatment of genital warts in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2186623" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Double-blind randomized clinical trial of self-administered podofilox solution versus vehicle in the treatment of genital warts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2564912" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Patient-applied podofilox for treatment of genital warts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2564912" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Patient-applied podofilox for treatment of genital warts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19709100" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Polyphenon E: a new treatment for external anogenital warts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25774455" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Expression patterns of immune-associated genes in external genital and perianal warts treated with sinecatechins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25275942" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Apoptotic gene expression in sinecatechins-treated external genital and perianal warts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23135094" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Green tea catechins: biologic properties, proposed mechanisms of action, and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18363746" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17958849" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A randomized, double-blind, four-arm parallel-group, placebo-controlled Phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon E in the treatment of external genital warts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18515521" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18515521" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2005249" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cryotherapy in the treatment of condylomata acuminata: a controlled study of 64 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11220242" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : [Clinical aspects and therapy of anogenital warts and papillomavirus-associated lesions].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23316984" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cutaneous cryosurgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6853811" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Surgical treatment of recalcitrant warts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10867470" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Electrocoagulation of perianal warts: a word of caution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24941064" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Low prevalence of oral and nasal human papillomavirus in employees performing CO2-laser evaporation of genital warts or loop electrode excision procedure of cervical dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26602622" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Human Papillomavirus and Genital Warts: A Review of the Evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8108758" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Treatment of external genital warts comparing cryotherapy (liquid nitrogen) and trichloroacetic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2597953" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Podophyllin versus scissor excision in the treatment of perianal condylomata acuminata: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12399673" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : CO(2) laser surgery for extensive, cauliflower-like anogenital condylomata acuminata: retrospective long-term study on 19 HIV-positive and 45 HIV-negative men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16638419" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : An evidence-based review of medical and surgical treatments of genital warts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24114691" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Comparing thulium laser and Nd:YAG laser in the treatment of genital and urethral condylomata acuminata in male patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8284887" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Laser treatment of urethral condyloma: a five-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16470844" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pulsed dye laser treatment of genital warts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11966796" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Treatment of anogenital warts by pulsed dye laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24699452" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The combination of CO2 laser vaporation and photodynamic therapy in treatment of condylomata acuminata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12902571" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20393949" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : 5-FU for genital warts in non-immunocompromised individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30078935" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Cantharidin is Superior to Trichloroacetic Acid for the Treatment of Non-mucosal Genital Warts: A Pilot Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10513659" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Intralesional or topical cidofovir (HPMPC, VISTIDE) for the treatment of recurrent genital warts in HIV-1-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11477525" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11403192" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Efficacy and tolerability of topical 1% cidofovir cream for the treatment of external anogenital warts in HIV-infected persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7666893" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11843219" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Resolution of recurrent perianal condylomata acuminata by topical cidofovir in patients with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11992585" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Local treatment of HPV-induced skin lesions by Cidofovir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10858720" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Successful treatment of recalcitrant condyloma with topical cidofovir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12907906" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Topical cidofovir (HPMPC) is an effective adjuvant to surgical treatment of anogenital condylomata acuminata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11834957" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Combined surgery and cidofovir is an effective treatment for genital warts in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19772554" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Interferon for the treatment of genital warts: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1916791" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Subcutaneous interferon alpha 2a combined with cryotherapy vs cryotherapy alone in the treatment of primary anogenital warts: a randomised observer blind placebo controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24819873" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Immunotherapy of HPV infection-caused genital warts using low dose cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23981645" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Low-dose oral cyclophosphamide therapy is effective for condylomata acuminata</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22113200" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Large benign condyloma acuminatum: successful treatment with isotretinoin and interferon alpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24703263" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Complete remission of recalcitrant genital warts with a combination approach of surgical debulking and oral isotretinoin in a patient with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2754052" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Comparative study of systemic interferon alfa-nl and isotretinoin in the treatment of resistant condylomata acuminata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8789431" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Comparative study of systemic interferon alfa-2a with oral isotretinoin and oral isotretinoin alone in the treatment of recurrent condylomata accuminata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25940810" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Combination Systemic Fluorouracil and Radiation for the Treatment of Recalcitrant Condyloma with Associated Squamous Cell Carcinoma in an Immunocompromised 15-Year-Old Girl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23311375" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Clinical and immunologic results of local hyperthermia at 44 °C for extensive genital warts in patients with diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17923396" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : External beam radiotherapy for extensive genital condyloma acuminate: a role in selected patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28819018" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Adjuvant treatment of anogenital warts with systemic interferon: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21571164" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Condyloma accuminatum treated with recombinant quadrivalent human papillomavirus vaccine (types 6, 11, 16, 18).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23244376" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Lack of efficacy in treating condyloma acuminata and preventing recurrences with the recombinant quadrivalent human papillomavirus vaccine in a case series of immunocompetent patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25922903" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Evaluation of the Efficacy, Safety, and Tolerability of 3 Dose Regimens of Topical Sodium Nitrite With Citric Acid in Patients With Anogenital Warts: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25103148" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Intralesional injection of Mycobacterium w vaccine vs imiquimod, 5%, cream in patients with anogenital warts: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26513041" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Efficacy and tolerability of nitric-zinc complex in the treatment of external genital warts and "difficult-to-treat" warts: a "proof of concept", prospective, multicentre, open study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22634446" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : A randomized trial of immunotherapy for persistent genital warts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22957266" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Effectiveness of glycyrrhizinic Acid (glizigen) and an immunostimulant (viusid) to treat anogenital warts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23651275" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : 5-aminolevulinic acid-based photodynamic therapy for the treatment of condylomata acuminata in Chinese patients: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24216675" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Clinical analysis of five methods used to treat condylomata acuminata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21729164" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : A randomized clinical comparative study of cryotherapy plus photodynamic therapy vs. cryotherapy in the treatment of multiple condylomata acuminata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30427239" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : 5-aminolevulinic acid photodynamic therapy for condyloma acuminatum of urethral meatus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31374308" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : 5-Aminolevulinic photodynamic therapy versus carbon dioxide laser therapy for small genital warts: A multicenter, randomized, open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28632472" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Recalcitrant giant condyloma acuminatum treated successfully with a novel combination of Mycobacterium indicus pranii immunotherapy and acitretin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18847553" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
